Kura Oncology (NASDAQ:KURA) Plunges 8.33% as Earnings Loom and Strategic Shifts Spark Caution

Kura Oncology (NASDAQ:KURA) plunged 8.33% in pre-market trading on December 10, 2025, as investor sentiment turned cautious ahead of its third-quarter earnings report and ongoing strategic developments.

Recent analyst activity highlighted mixed signals. While Zacks Research upgraded the stock, several firms including Cantor Fitzgerald and Brookline Capital Management trimmed 2025 earnings forecasts, reflecting uncertainty over the company’s path to profitability despite a 42.7% revenue growth narrative. Persistent losses and elevated R&D expenses remain key concerns for market participants.

Positive catalysts emerged from Kura’s partnership with Kyowa Kirin, including a $30 million milestone payment and advancing ziftomenib trials for acute myeloid leukemia. The FDA’s recent approval of KOMZIFTI™ also underscored therapeutic progress. However, these developments failed to offset near-term financial pressures and downgraded expectations, weighing on share prices ahead of the earnings release.